Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
36 Cards in this Set
- Front
- Back
|
Antimetabolites
|
CCS Drugs:
Methotrexate 5-Fluorouracil Cytarabine Azathioprine/Mercaptopurine Capecitabine |
|
|
Alkylating Agents
|
CCNS Drugs:
Cyclophosphamide Carmustine Temozolamide Cisplatin |
|
|
Natural Products
|
CCS (M-phase) Drugs:
Vincristine Vinblastine Etoposide Topotecan Paclitaxel |
|
|
Hormones
|
Tamoxfen
Anastrozole Fulvestrant Flutamide Finasteride Leuprolide |
|
|
Cytotoxic Antibiotics
|
Intercalating Agents:
Daunorubicin Doxorubicin Dactinomycin Bleomycin |
|
|
Monoclonal Antibodies
|
Rituximab
Trastuzumab |
|
|
Others
|
Asparaginase
Imatinib Mesylate Hydroxyurea |
|
|
Methotrexate
|
MoA: competitive and reversible DHRF inhibitor;
RoA: oral, IV, intrathecal; Clinical Uses: solid tumors, immunosuppressive in graft rejection control, RA; Antidote: Leucovorin (aka-folinic acid, for cancer tx.); Folate (for RA tx); AE: nephrotoxicity; CI: PREGNANCY |
|
|
5-Fluorouracil
|
MoA: interferes with RNA function and inhibits DNA synthesis;
Clinical Uses: cancers of bladder, prostate, pancreas, oropharnygeal, colon, and kidney; (5-FU + leucovorin is used for colon cancer); |
|
|
Capecitabine
|
MoA: inhibits thymidylate synthase; oral prodrug converted to 5-FU;
Clinical Uses: used with paclitaxel and doxorubicin in the tx of resistant colorectal or metastatic breast cancers |
|
|
Cytarabine
|
MoA: blocks elongation of DNA synthesis;
Clinical Uses: DOC for AML; AE: Neurotoxicity |
|
|
Azathioprine/Mercaptopurine
|
MoA: inhibits PRPP synthetase blocking de novo purine synthesis;
Clinical Uses: immunosuppressants, RA, antimalignants; AE: bone marrow suppression, leukopenia |
|
|
Cyclophosphamide
|
MoA: prodrug converted in the liver; affects DNA and RNA synthesis;
RoA: oral, IV; Clinical Uses: leukemia, solid tumors, NHL, ovarian cancer, neuroblastoma, immunosuppressive to prevent graft rejection, SLE; Other: metabolized to mustard (nephrotoxic causing SIADH, antidote: demeclocycline) and acrolein (causes hemorrhagic cystitis, antidote: mesna) |
|
|
Carmustine
|
Clinical Uses: CNS cancers since it can cross the BBB
|
|
|
Temozolamide
|
Clinical Uses: tx of malignant gliomas since it can also cross the BBB
|
|
|
Cisplatin
|
MoA: inhibits replication and transcription;
Clinical Uses: urogenital cancers; RoA: IV or rapid injection (needle must not contain aluminum!!); Antidote: amifostine; AE: nephrotoxicity and ototoxicity |
|
|
Vincristine
|
MoA: binds to tubulin and blocks assembly of microtubules;
Clinical Uses: pediatric leukemias, solid tumors, Hodgkins, rhabdomyosarcoma, lymphomas, neuroblastomas; AE: peripheral neuropathy (christ my nerves!) |
|
|
Vinblastine
|
MoA: bind to tubulin and prevents assembly of microtubules;
Clinical Uses: Hodgkins, testicular carcinoma; AE: reversible myelosuppression, leukopenia, alopecia (blast my bones!) |
|
|
Etoposide
|
MoA: Topo 2 complex inhibitor;
Clinical Uses: first time and metastatic testicular cancer; AE: dose limiting leukopenia; CAUSES AML!!! |
|
|
Topotecan
|
MoA: Topo 1 complex inhibitor;
AE: dose limiting neutropenia |
|
|
Paclitaxel
|
MoA: inhibits microtubule DISassembly;
Clinical Uses: ovarian & breast cancer; lung, esophageal, bladder, head & neck cancer; AE: HS rxns, neutropenia, cardiac conduction defects |
|
|
Tamoxifen
|
MoA: selective estrogen receptor modulator (SERM), blocks binding of estrogen to its receptor in breast cancer;
Clinical Uses: tx and prophylaxis of breast cancer; infertility, gynecomastia; AE: hot flashes, vaginal bleeding, hypercalemia, peripheral edema |
|
|
Anastrozole
|
MoA: aromatase inhibitor, prevents estrogen synthesis;
Clinical Uses: breast cancer |
|
|
Fulvestrant
|
MoA: estrogen receptor antagonist;
Clinical Uses: metastatic breast cancer in post-menopausal women |
|
|
Flutamide
|
MoA: androgen receptor antagonist;
Clinical Uses: prostate cancer |
|
|
Finasteride
|
MoA: inhibits 5-alpha-reductase, which inhibits the synthesis of testosterone to DHT;
Clinical Uses: BPH and male pattern baldness |
|
|
Leuprolide
|
MoA: GNRH receptor agonist;
Clinical Uses: used in hormone responsive cancers such as prostate and breast cancer; endometriosis |
|
|
Daunorubicin
|
MoA: Topo 2 complex inhibitor;
Clinical Uses: Leukemia, NHL; AE: cardio toxicity and red urine |
|
|
Doxorubicin
|
MoA: Topo 2 complex inhibitor;
Clinical Uses: solid tumors of the breast, endometrium, testes, and lung; ABVD in Hodgkin's; CHOP in NHL; osteogenic and Ewing's sarcoma, soft tissue sarcoma; metastatic carcinoma of the thryoid; Antidote: dexrazoxane (FE chelator); AE: cardio toxicity |
|
|
Dactinomycin
|
MoA: binds DNA helix and prevents transcription of DNA by RNA polymerase;
Clinical Uses: rhabdomyosarcoma, Wilm's tumor, Ewing's tumor, Kaposi's sarcoma; RoA: IV; AE: hematopoietic suppression, pancytopenia-dose limiting property |
|
|
Bleomycin
|
MoA: inhibits cell cycle at G2; blows DNA apart;
Clinical Uses: testicular cancers; squamous cell carcinomas of head, neck, and lungs; lymphomas; AE: pulmonary toxicity and pulmonary fibrosis |
|
|
Rituximab
|
MoA: chimeric anti-CD20 monoclonal antibody that binds to the CD20 antigen on follicular B cells;
Clinical Uses: Non Hodgkins Lymphoma (NHL) |
|
|
Trastuzumab
|
MoA: recombinant human monocolonal antibody that binds EGF-R2;
Clinical Uses: breast cancer (HER2/NEU); AE: cardio toxicity |
|
|
Asparaginase
|
MoA: deprives cancer cells of asparagine needed for protein synthesis, leads to cell death by activation of apoptosis;
RoA: IV Clinical Uses: ALL; Toxicity: alopecia; HS rxns; toxic to CNS at high doses; clotting abnormalities |
|
|
Imatinib Mesylate
|
MoA: inhibits the BCR-ABL tyrosine kinase translocation of the Philadelphia chromosome;
Clinical Uses: CML |
|
|
Hyrdoxyurea
|
MoA: inhibits ribonucleotide reductase;
Clinical Uses: myeloproliferative disorders: CML, PV, ET, etc. |
